×
About 1,455 results

ALLMedicine™ Anaplastic Thyroid Carcinoma Center

Research & Reviews  713 results

Prognostic Factors and Survival Score for Patients With Anaplastic Thyroid Carcinoma: A...
https://doi.org/10.21873/anticanres.14915
Anticancer Research; Marchand-Crety C, Pascard M et. al.

Mar 31st, 2021 - Anaplastic thyroid carcinoma (ATC) is the least common but most lethal of thyroid cancer, despite various therapeutic options, with limited efficacy. In order to help therapeutic decision-making, the purpose of this study was to develop a new prog...

Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
https://doi.org/10.1089/thy.2020.0296
Thyroid : Official Journal of the American Thyroid Associ... Qin Y, Wang JR et. al.

Feb 18th, 2021 - Background: Anaplastic thyroid carcinoma (ATC) is an aggressive thyroid cancer that requires a rapid diagnosis and treatment to achieve disease control. Gene mutation profiling of circulating cell-free DNA (cfDNA) in peripheral blood may help to f...

Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinom...
https://doi.org/10.20945/2359-3997000000325
Archives of Endocrinology and Metabolism; Bueno F, Abelleira E et. al.

Feb 15th, 2021 - Anaplastic thyroid carcinoma is the rarest tumor of the thyroid gland, representing less than 2% of clinically recognized thyroid cancers. Typically, it has an extremely rapid onset, fatal outcomes in most cases, and a median overall survival of 3...

Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics.
https://doi.org/10.1007/s11912-021-01019-9 10.1097/00000658-200003000-00005 10.1038/s41467-019-10680-5 10.1093/hmg/ddu749 10.3390/cancers11030402 10.1158/1078-0432.CCR-18-0373 10.1007/s12020-016-1080-9 10.1002/hed.25634 10.1089/thy.2015.0506 10.1111/his.13942 10.1172/JCI85271 10.1158/1078-0432.CCR-17-2297 10.18632/oncotarget.17300 10.1016/j.humpath.2018.07.027 10.1089/thy.2016.0254 10.1002/(sici)1097-0215(19970422)74:2<212::aid-ijc13>3.0.co;2-f 10.1038/nrc2723 10.1677/ERC-08-0154 10.21037/atm.2016.12.40 10.1002/cam4.2467 10.1210/jc.2013-3734 10.1210/jc.2014-3606 10.1136/pgmj.2007.064881 10.1371/journal.pgen.1006239 10.1038/nrc.2017.79 10.1038/s41388-018-0171-x 10.14670/HH-18-079 10.1097/PAT.0b013e328360b61d 10.1056/NEJMc1215697 10.1111/his.12964 10.1016/j.humpath.2009.09.023 10.1016/j.yexmp.2015.09.006 10.1093/jnci/djx227 10.1016/j.ejca.2019.10.017 10.1200/JCO.2017.74.5497 10.1200/JCO.2018.78.5097 10.1001/jama.2013.3190 10.1200/JCO.2014.56.8253 10.2174/1381612822666160614000053 10.1038/nrc3860 10.1038/sj.bjc.6602970 10.1371/journal.pone.0022769 10.1080/0284186X.2019.1664764 10.1038/nrm3330 10.1038/nature05933 10.1038/ng.3779 10.1038/onc.2009.4 10.1136/jclinpath-2013-201991 10.1111/1759-7714.12613 10.1016/S1470-2045(15)00077-7 10.1210/jc.2008-0273 10.1158/1078-0432.CCR-16-1679 10.1016/j.yexcr.2016.09.010 10.1016/j.critrevonc.2016.04.006 10.1016/j.yexcr.2017.05.021 10.2174/1568009618666180308105727 10.1007/978-1-4939-7734-5_22 10.1016/j.yexcr.2018.06.025 10.1111/cas.14220 10.1016/j.gene.2019.02.046 10.1007/978-1-0716-0377-2_18 10.3892/mmr.2017.7477 10.3892/mmr.2015.3151 10.1038/s41388-017-0088-9 10.1210/jc.2007-2696 10.1677/ERC-07-0129 10.1038/ncb2173 10.4161/auto.9064 10.1016/j.cell.2005.01.014 10.2174/1568009618666180628154727 10.1530/ERC-17-0497 10.3390/cells7120265 10.1007/s12020-017-1393-3 10.1016/j.humpath.2015.12.018 10.1245/s10434-008-0005-0 10.1245/aso.2002.9.1.57 10.3349/ymj.2005.46.6.759 10.1089/thy.2012.0302 10.1002/1097-0142(20010615)91:12<2335::AID-CNCR1266>3.0.CO;2-1 10.1089/thy.2000.10.587 10.1089/thy.2009.0115 10.1111/j.2042-7158.2012.01567.x 10.1016/j.ejphar.2014.07.025 10.1002/1097-0142(19851101)56:9<2155::aid-cncr2820560903>3.0.co;2-e 10.1093/jnci/83.4.288 10.1126/science.2683079 10.1016/j.bbrc.2010.12.018 10.1089/thy.2016.0072 10.1210/jc.2009-2827 10.1089/thy.2007.0120 10.1089/thy.2010.0057 10.1210/jc.2012-1520 10.1007/s00280-014-2604-8 10.1016/j.ejca.2017.01.029 10.1089/thy.2012.0103 10.1089/thy.2016.0621 10.2217/fon-2018-0557 10.1056/NEJMoa1502309 10.1210/jc.2016-2525 10.3389/fonc.2019.00106 10.1038/sj.bjc.6602461 10.1056/NEJM200104053441401 10.1210/jc.2002-021230 10.1210/jc.2003-031734 10.1073/pnas.85.23.9302 10.1007/s11912-007-0007-2 10.1007/s11912-011-0154-3 10.1158/1535-7163.MCT-03-0156 10.1016/j.hoc.2008.11.006 10.1210/jc.2013-1364 10.1158/0008-5472.CAN-04-1443 10.1158/1535-7163.MCT-06-0595 10.3892/ijo.2019.4881 10.2217/fon.15.68 10.3892/or.2018.6306 10.1158/1078-0432.CCR-14-0776 10.1038/sj.jid.5700632 10.1089/thy.2013.0149 10.3892/ijo.2016.3723 10.1200/JCO.2017.73.6785 10.1016/j.humpath.2013.03.014 10.3390/ijms13021886 10.1055/s-0029-1224116 10.1200/JCO.2013.49.6596 10.1089/thy.2019.0202 10.1089/thy.2019.0477 10.1634/theoncologist.2016-0455 10.18632/oncotarget.13310 10.1016/S1470-2045(17)30691-5 10.1210/jc.2014-2359 10.1158/1078-0432.CCR-06-2636 10.1089/thy.2008.0321 10.1016/S1470-2045(04)01509-8 10.1210/jc.2013-1106 10.1016/j.tranon.2018.08.005 10.1038/s41368-020-0084-8 10.1016/S1470-2045(17)30607-1 10.1007/978-1-0716-0377-2_21 10.1530/ERC-16-0421 10.1007/s12020-019-01865-5 10.1186/s40425-018-0378-y 10.1089/thy.2019.0133 10.1155/2015/726085 10.1016/j.anl.2009.02.001 10.1507/endocrj.k08e-016 10.3109/0284186X.2015.1102966 10.1089/thy.2009.0025 10.1155/2011/583978 10.1016/j.amjoto.2014.03.006
Current Oncology Reports; Abe I, Lam AK

Feb 14th, 2021 - Anaplastic thyroid carcinoma is a type of thyroid carcinoma with the most aggressive biological behaviour amongst thyroid cancer. Here, we review the current genomic and the impacts of advances in therapies to improve the management of patients wi...

The Lenvatinib/Pembrolizumab combination is an effective treatment option for anaplasti...
https://doi.org/10.1089/thy.2020.0322
Thyroid : Official Journal of the American Thyroid Associ... Dierks C, Seufert J et. al.

Jan 29th, 2021 - Anaplastic thyroid carcinoma (ATC) and metastasized poorly differentiated thyroid carcinomas (PDTC) are rare aggressive malignancies with poor overall survival despite extensive multimodal therapy. Tumors are highly proliferative, with frequently ...

see more →

Guidelines  2 results

American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid C...
https://www.liebertpub.com/doi/10.1089/thy.2012.0302
Robert C. Smallridge

Nov 5th, 2012 - These are the first comprehensive guidelines for ATC and provide recommendations for management of this extremely aggressive malignancy. Patients with stage IVA/IVB resectable disease have the best prognosis, particularly if a multimodal approach.

The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons: Core questions and recommendations for treatments of thyroid cancer
https://www.jstage.jst.go.jp/article/endocrj/advpub/0/advpub_EJ20-0025/_pdf/-char/en
Endocrine Journal;

 The Japan Associations of Endocrine Surgeons has developed the revised version of the Clinical Practice Guidelines for Thyroid Tumors. This article describes the guidelines translated into English for the 35 clinical questions relevant to the t...

see more →

Clinicaltrials.gov  729 results

Prognostic Factors and Survival Score for Patients With Anaplastic Thyroid Carcinoma: A...
https://doi.org/10.21873/anticanres.14915
Anticancer Research; Marchand-Crety C, Pascard M et. al.

Mar 31st, 2021 - Anaplastic thyroid carcinoma (ATC) is the least common but most lethal of thyroid cancer, despite various therapeutic options, with limited efficacy. In order to help therapeutic decision-making, the purpose of this study was to develop a new prog...

Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
https://doi.org/10.1089/thy.2020.0296
Thyroid : Official Journal of the American Thyroid Associ... Qin Y, Wang JR et. al.

Feb 18th, 2021 - Background: Anaplastic thyroid carcinoma (ATC) is an aggressive thyroid cancer that requires a rapid diagnosis and treatment to achieve disease control. Gene mutation profiling of circulating cell-free DNA (cfDNA) in peripheral blood may help to f...

Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinom...
https://doi.org/10.20945/2359-3997000000325
Archives of Endocrinology and Metabolism; Bueno F, Abelleira E et. al.

Feb 15th, 2021 - Anaplastic thyroid carcinoma is the rarest tumor of the thyroid gland, representing less than 2% of clinically recognized thyroid cancers. Typically, it has an extremely rapid onset, fatal outcomes in most cases, and a median overall survival of 3...

Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics.
https://doi.org/10.1007/s11912-021-01019-9 10.1097/00000658-200003000-00005 10.1038/s41467-019-10680-5 10.1093/hmg/ddu749 10.3390/cancers11030402 10.1158/1078-0432.CCR-18-0373 10.1007/s12020-016-1080-9 10.1002/hed.25634 10.1089/thy.2015.0506 10.1111/his.13942 10.1172/JCI85271 10.1158/1078-0432.CCR-17-2297 10.18632/oncotarget.17300 10.1016/j.humpath.2018.07.027 10.1089/thy.2016.0254 10.1002/(sici)1097-0215(19970422)74:2<212::aid-ijc13>3.0.co;2-f 10.1038/nrc2723 10.1677/ERC-08-0154 10.21037/atm.2016.12.40 10.1002/cam4.2467 10.1210/jc.2013-3734 10.1210/jc.2014-3606 10.1136/pgmj.2007.064881 10.1371/journal.pgen.1006239 10.1038/nrc.2017.79 10.1038/s41388-018-0171-x 10.14670/HH-18-079 10.1097/PAT.0b013e328360b61d 10.1056/NEJMc1215697 10.1111/his.12964 10.1016/j.humpath.2009.09.023 10.1016/j.yexmp.2015.09.006 10.1093/jnci/djx227 10.1016/j.ejca.2019.10.017 10.1200/JCO.2017.74.5497 10.1200/JCO.2018.78.5097 10.1001/jama.2013.3190 10.1200/JCO.2014.56.8253 10.2174/1381612822666160614000053 10.1038/nrc3860 10.1038/sj.bjc.6602970 10.1371/journal.pone.0022769 10.1080/0284186X.2019.1664764 10.1038/nrm3330 10.1038/nature05933 10.1038/ng.3779 10.1038/onc.2009.4 10.1136/jclinpath-2013-201991 10.1111/1759-7714.12613 10.1016/S1470-2045(15)00077-7 10.1210/jc.2008-0273 10.1158/1078-0432.CCR-16-1679 10.1016/j.yexcr.2016.09.010 10.1016/j.critrevonc.2016.04.006 10.1016/j.yexcr.2017.05.021 10.2174/1568009618666180308105727 10.1007/978-1-4939-7734-5_22 10.1016/j.yexcr.2018.06.025 10.1111/cas.14220 10.1016/j.gene.2019.02.046 10.1007/978-1-0716-0377-2_18 10.3892/mmr.2017.7477 10.3892/mmr.2015.3151 10.1038/s41388-017-0088-9 10.1210/jc.2007-2696 10.1677/ERC-07-0129 10.1038/ncb2173 10.4161/auto.9064 10.1016/j.cell.2005.01.014 10.2174/1568009618666180628154727 10.1530/ERC-17-0497 10.3390/cells7120265 10.1007/s12020-017-1393-3 10.1016/j.humpath.2015.12.018 10.1245/s10434-008-0005-0 10.1245/aso.2002.9.1.57 10.3349/ymj.2005.46.6.759 10.1089/thy.2012.0302 10.1002/1097-0142(20010615)91:12<2335::AID-CNCR1266>3.0.CO;2-1 10.1089/thy.2000.10.587 10.1089/thy.2009.0115 10.1111/j.2042-7158.2012.01567.x 10.1016/j.ejphar.2014.07.025 10.1002/1097-0142(19851101)56:9<2155::aid-cncr2820560903>3.0.co;2-e 10.1093/jnci/83.4.288 10.1126/science.2683079 10.1016/j.bbrc.2010.12.018 10.1089/thy.2016.0072 10.1210/jc.2009-2827 10.1089/thy.2007.0120 10.1089/thy.2010.0057 10.1210/jc.2012-1520 10.1007/s00280-014-2604-8 10.1016/j.ejca.2017.01.029 10.1089/thy.2012.0103 10.1089/thy.2016.0621 10.2217/fon-2018-0557 10.1056/NEJMoa1502309 10.1210/jc.2016-2525 10.3389/fonc.2019.00106 10.1038/sj.bjc.6602461 10.1056/NEJM200104053441401 10.1210/jc.2002-021230 10.1210/jc.2003-031734 10.1073/pnas.85.23.9302 10.1007/s11912-007-0007-2 10.1007/s11912-011-0154-3 10.1158/1535-7163.MCT-03-0156 10.1016/j.hoc.2008.11.006 10.1210/jc.2013-1364 10.1158/0008-5472.CAN-04-1443 10.1158/1535-7163.MCT-06-0595 10.3892/ijo.2019.4881 10.2217/fon.15.68 10.3892/or.2018.6306 10.1158/1078-0432.CCR-14-0776 10.1038/sj.jid.5700632 10.1089/thy.2013.0149 10.3892/ijo.2016.3723 10.1200/JCO.2017.73.6785 10.1016/j.humpath.2013.03.014 10.3390/ijms13021886 10.1055/s-0029-1224116 10.1200/JCO.2013.49.6596 10.1089/thy.2019.0202 10.1089/thy.2019.0477 10.1634/theoncologist.2016-0455 10.18632/oncotarget.13310 10.1016/S1470-2045(17)30691-5 10.1210/jc.2014-2359 10.1158/1078-0432.CCR-06-2636 10.1089/thy.2008.0321 10.1016/S1470-2045(04)01509-8 10.1210/jc.2013-1106 10.1016/j.tranon.2018.08.005 10.1038/s41368-020-0084-8 10.1016/S1470-2045(17)30607-1 10.1007/978-1-0716-0377-2_21 10.1530/ERC-16-0421 10.1007/s12020-019-01865-5 10.1186/s40425-018-0378-y 10.1089/thy.2019.0133 10.1155/2015/726085 10.1016/j.anl.2009.02.001 10.1507/endocrj.k08e-016 10.3109/0284186X.2015.1102966 10.1089/thy.2009.0025 10.1155/2011/583978 10.1016/j.amjoto.2014.03.006
Current Oncology Reports; Abe I, Lam AK

Feb 14th, 2021 - Anaplastic thyroid carcinoma is a type of thyroid carcinoma with the most aggressive biological behaviour amongst thyroid cancer. Here, we review the current genomic and the impacts of advances in therapies to improve the management of patients wi...

The Lenvatinib/Pembrolizumab combination is an effective treatment option for anaplasti...
https://doi.org/10.1089/thy.2020.0322
Thyroid : Official Journal of the American Thyroid Associ... Dierks C, Seufert J et. al.

Jan 29th, 2021 - Anaplastic thyroid carcinoma (ATC) and metastasized poorly differentiated thyroid carcinomas (PDTC) are rare aggressive malignancies with poor overall survival despite extensive multimodal therapy. Tumors are highly proliferative, with frequently ...

see more →

News  11 results

Targeted Treatment Tied to Longer Survival in Patients With Anaplastic Thyroid Cancer
https://www.medscape.com/viewarticle/936044

Aug 20th, 2020 - NEW YORK (Reuters Health) - With the introduction of targeted treatments for anaplastic thyroid carcinoma, patients have seen significant improvements in survival, according to a new report. "Over the last 5 years, a greater understanding of the m...

Targeted Treatment Tied to Longer Survival in Patients With Anaplastic Thyroid Cancer
https://www.staging.medscape.com/viewarticle/936044

Aug 20th, 2020 - NEW YORK (Reuters Health) - With the introduction of targeted treatments for anaplastic thyroid carcinoma, patients have seen significant improvements in survival, according to a new report. "Over the last 5 years, a greater understanding of the m...

Lichenoid dermatitis with mycosis fungoides features linked to checkpoint inhibitor therapy
https://www.mdedge.com/hematology-oncology/article/205419/immunotherapy/lichenoid-dermatitis-mycosis-fungoides-features?channel=39313
Bianca Nogrady

Jul 28th, 2019 - A patient treated with immune checkpoint inhibitor therapy for thyroid carcinoma presented with lichenoid dermatitis that resembled mycosis fungoides and also showed with monoclonal T-cell receptor gene rearrangement. A case report published in th.

Aggressive Approach to Anaplastic Thyroid Cancer Shows Benefit
https://www.medscape.com/viewarticle/852901

Oct 19th, 2015 - ORLANDO, Florida — Survival rates of the rare anaplastic thyroid carcinoma, which has a very poor prognosis, show significant improvement when patients are treated with an aggressive combined-modality therapy, although the toxicities associated wi...

Aggressive Approach to Anaplastic Thyroid Cancer Shows Benefit
https://www.staging.medscape.com/viewarticle/852901

Oct 19th, 2015 - ORLANDO, Florida — Survival rates of the rare anaplastic thyroid carcinoma, which has a very poor prognosis, show significant improvement when patients are treated with an aggressive combined-modality therapy, although the toxicities associated wi...

see more →